Drug
Vixarelimab
Vixarelimab: highest development phase Phase 2, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vixarelimab NCT03816891 | Phase 2 | Prurigo Nodularis |
Latest
No recent events.
Follow Vixarelimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.